Skip to main content

Table 1 Demographic and clinical characteristics of the 144 patients with KPC Kp invasive infection included in the study

From: Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case–control study

Variable Number (%) of patients p value
DC group (n = 48) ST group (n = 96)
Demographics and comorbidities
 Age (years), mean ± SD 55.5 ± 15 61.3 ± 12 0.06
 Males 35 (72.9) 58 (60.4) 0.19
 CHF 18 (37.5) 27 (28.1) 0.34
 COPD 11 (22.9) 12 (12.5) 0.17
 CRF 8 (16.7) 7 (7.3) 0.15
 Diabetes 17 (35.4) 31 (32.3) 0.85
 CLD 10 (20.8) 8 (8.3) 0.06
 Neoplasm 2 (4.2) 12 (12.5) 0.21
 Immunosuppressive status 19 (39.6) 26 (27.1) 0.18
 ICU stay before infection (days), median (IQR) 11 (4–24) 7 (1-22.5) 0.08
 Duration of MV before infection (days), median (IQR) 6 (1.5-15.5) 5 (1–14) 0.57
 Duration of vasopressors before infection (days), median (IQR) 3 (1–10) 1.5 (0–6) 0.11
Presenting feature
 Medical admission 25 (52.1) 59 (61.5) 0.37
 Surgical admission 18 (37.5) 30 (31.3) 0.28
 Trauma admission 5 (10.4) 11 (11.5) 0.92
SAPS II score, median (IQR) 44 (36–56) 46 (36–57) 0.56
SOFA score at infection, median (IQR) 9 (7–11) 8 (6–10) 0.33
Septic shock on occurrence of infection 36 (75) 43 (44.8) <0.01
ARDS on occurrence of infection 18 (37.5) 23 (23.9) 0.13
CRRT on occurrence of infection 20 (41.7) 26 (27.1) 0.13
PCT on occurrence of infection (ng/ml), median (interval) 6.1 (3.2–50.4) 3.1 (0.8–5.9) <0.01
Type of infection
 Pneumonia 25 (52.1) 49 (51) 0.95
 IAI 9 (18.7) 10 (10.4) 0.19
 SSTI 1 (2.1) 11 (11.5) 0.06
 UTI 3 (6.2) 9 (9.3) 0.75
 CVC BSI 8 (16.7) 10 (10.4) 0.42
 Primary BSI 6 (12.5) 10 (10.4) 0.92
 Secondary BSI 23 (47.9) 26 (27.1) 0.02
 Multiple site infection 4 (8.2) 3 (3.1) 0.54
Therapeutic aspects
 IIAT 13 (27.1) 40 (41.7) 0.16
 Overall duration of treatment (days), median (interval) 17 (11.5–25.5) 11.5 (7.5–15.5) <0.01
Clinical and microbiological outcome
 28-day mortality 14 (29.2) 46 (47.9) 0.04
 90-day mortality 24 (50) 58 (60.4) 0.31
 Clinical cure 30 (62.5) 47 (48.9) 0.17
 Microbiological eradicationa 22 (50) 31 (38.3) 0.27
 Duration of MV after infection (days), median (interval) 14 (7.5–31) 11.5 (7–19) 0.16
 Duration of vasopressors after infection (days), median (interval) 10.5 (3.5–27.5) 8 (4.5–12) 0.19
  1. Data presented as N (%), unless otherwise indicated. Bold data are significant
  2. IQR interquartile range, KPC Klebsiella pneumoniae carbapenemase, Kp Klebsiella pneumoniae, DC double carbapenem, ST standard treatment, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, MV mechanical ventilation, ARDS acute respiratory distress syndrome, CRRT continuous renal replacement therapy, PCT procalcitonin, CHF chronic heart failure, COPD chronic obstructive pulmonary disease, CRF chronic renal failure, CLD chronic liver disease, IAI intra-abdominal infection, SSTI skin and soft tissue infection, UTI urinary tract infection, CVC central vascular catheter, BSI bloodstream infection, IIAT initial inappropriate antimicrobial therapy
  3. aMicrobiological outcome was analyzed in 125 patients: 44 patients (DC group) and 81 patients (ST group)